| no |
title |
author |
magazine |
year |
volume |
issue |
page(s) |
type |
| 1 |
Androgen-deprivation therapies for prostate cancer and risk of infection by SARS-CoV-2: a population-based study (N = 4532)
|
Montopoli, M.
|
|
|
31 |
8 |
p. 1040-1045
|
article
|
| 2 |
Are we ready to accept intermediate outcome measures in clinical cancer trials?
|
Grünwald, V.
|
|
|
31 |
8 |
p. 973-975
|
article
|
| 3 |
Characterizing diversity in the tumor-immune microenvironment of distinct subclasses of gastroesophageal adenocarcinomas
|
Derks, S.
|
|
|
31 |
8 |
p. 1011-1020
|
article
|
| 4 |
Clinical and molecular characteristics and treatment outcomes of advanced right-colon, left-colon and rectal cancers: data from 1180 patients in a phase III trial of panitumumab with an extended biomarker panel
|
Seligmann, J.F.
|
|
|
31 |
8 |
p. 1021-1029
|
article
|
| 5 |
Collateral damage: the impact on outcomes from cancer surgery of the COVID-19 pandemic
|
Sud, A.
|
|
|
31 |
8 |
p. 1065-1074
|
article
|
| 6 |
Corrigendum to “Differential expression of various miRNAs in pediatric cytogenetically normal acute myeloid leukemia (CN-AML)”
|
Gaur, V.
|
|
|
31 |
8 |
p. 1092
|
article
|
| 7 |
Corrigendum to “Fertility and gonadal function in female survivors after treatment of early unfavorable Hodgkin lymphoma (HL) within the German Hodgkin Study Group HD14 trial”
|
Behringer, K.
|
|
|
31 |
8 |
p. 1093
|
article
|
| 8 |
Corrigendum to ‘Randomized, double-blind, placebo-controlled phase II study of istiratumab (MM-141) plus nab-paclitaxel and gemcitabine versus nab-paclitaxel and gemcitabine in front-line metastatic pancreatic cancer (CARRIE)’
|
Kundranda, M.
|
|
|
31 |
8 |
p. 1094
|
article
|
| 9 |
Corrigendum to ‘Socioeconomic and Administrative Factors Associated with Healthcare Delay and Treatment of Esophageal and Gastric Carcinoma: Experience at a Tertiary Care Centre in a Developing Country’
|
Hassan, S.
|
|
|
31 |
8 |
p. 1095
|
article
|
| 10 |
Do patients with cancer have a poorer prognosis of COVID-19? An experience in New York City
|
Miyashita, H.
|
|
|
31 |
8 |
p. 1088-1089
|
article
|
| 11 |
Editorial Board
|
|
|
|
31 |
8 |
p. v
|
article
|
| 12 |
Enrichment of kinase fusions in ESR1 wild-type, metastatic breast cancer revealed by a systematic analysis of 4854 patients
|
Ross, D.S.
|
|
|
31 |
8 |
p. 991-1000
|
article
|
| 13 |
Expanding the landscape of actionable genomic alterations in metastatic breast cancer: comprehensive genomic profiling for all?
|
Hilbers, F.S.
|
|
|
31 |
8 |
p. 967-969
|
article
|
| 14 |
Germline-somatic fluidity in guiding patient care
|
Hahn, E.
|
|
|
31 |
8 |
p. 1089-1090
|
article
|
| 15 |
Health-related quality of life after chemotherapy with or without rituximab in primary central nervous system lymphoma patients: results from a randomised phase III study
|
van der Meulen, M.
|
|
|
31 |
8 |
p. 1046-1055
|
article
|
| 16 |
Important considerations prior to elimination of breast cancer surgery after neoadjuvant systemic therapy: Listening to what our patients want
|
Caballero, C.
|
|
|
31 |
8 |
p. 1083-1084
|
article
|
| 17 |
Lower detection rates of SARS-COV2 antibodies in cancer patients versus health care workers after symptomatic COVID-19
|
Solodky, M.L.
|
|
|
31 |
8 |
p. 1087-1088
|
article
|
| 18 |
Management of early melanoma recurrence despite adjuvant anti-PD-1 antibody therapy☆
|
Owen, C.N.
|
|
|
31 |
8 |
p. 1075-1082
|
article
|
| 19 |
Management of hepatocellular carcinoma in the time of COVID-19
|
Iavarone, M.
|
|
|
31 |
8 |
p. 1084-1085
|
article
|
| 20 |
Neoantigen prediction and computational perspectives towards clinical benefit: recommendations from the ESMO Precision Medicine Working Group
|
De Mattos-Arruda, L.
|
|
|
31 |
8 |
p. 978-990
|
article
|
| 21 |
Reply to the Letter to the Editor ‘Germline-somatic fluidity in guiding patient care. Reply to the Letter to the Editor “Choice of control tissue impacts designation of germline variants in a cohort of papillary thyroid carcinoma patients” by J. C. Rubinstein et al.’ by E. Hahn & G. S. Charames
|
Christison-Lagay, E.R.
|
|
|
31 |
8 |
p. 1090-1091
|
article
|
| 22 |
Reply to the letter to the editor ‘Neutropenia in metastatic colorectal cancer receiving trifluridine/tipiracil’ by Colloca et al.
|
Yoshino, T.
|
|
|
31 |
8 |
p. 1085-1087
|
article
|
| 23 |
Table of Contents
|
|
|
|
31 |
8 |
p. iii-iv
|
article
|
| 24 |
Tackling diversity within diversity
|
Lomnicki, S.
|
|
|
31 |
8 |
p. 970-972
|
article
|
| 25 |
Time course and management of key adverse events during the randomized phase III SOLAR-1 study of PI3K inhibitor alpelisib plus fulvestrant in patients with HR-positive advanced breast cancer
|
Rugo, H.S.
|
|
|
31 |
8 |
p. 1001-1010
|
article
|
| 26 |
Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma
|
Choueiri, T.K.
|
|
|
31 |
8 |
p. 1030-1039
|
article
|
| 27 |
Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study
|
Mok, T.
|
|
|
31 |
8 |
p. 1056-1064
|
article
|
| 28 |
What is the value of health-related quality of life in a negative superiority trial?
|
Nakamura, K.
|
|
|
31 |
8 |
p. 976-977
|
article
|
Journal description